Our Pipeline

Our Pipeline With Promise

Portfolio In Development

EQRx has more than 10 programs in our portfolio of potential medicines, including both small molecules and biologics, with five clinical-stage programs, and several preclinical and drug engineering programs. We strive to create best-in-class medicines that can make a meaningful impact for patients.

In order to assemble our portfolio, our current clinical-stage assets were in-licensed from biopharma companies around the world. In addition, we have entered into multiple drug engineering collaborations with leading technology platform companies, including those with technology-enabled experimental platforms, machine-learning computational platforms, and physics-based computational platforms, to efficiently engineer molecules against well-specified targets for important chronic and life-threatening conditions.

Legend

Ongoing Trials
Planned Trials
Program
Target
Phase 1
Phase 2
Phase 3
Approval

Aumolertinib

EGFR

EGFR-mutated metastatic or locally advanced NSCLC

Phase 3

Adjuvant therapy in EGFR-mutated NSCLC

Phase 3

Aumolertinib (EQ143, HS-10296) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR-sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR. Aumolertinib was discovered by Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma), and EQRx has partnered with Hansoh Pharma on global development of aumolertinib.

EQRx holds the development and commercialization rights to aumolertinib outside of Greater China.

Hansoh Pharma holds the development and commercialization rights to aumolertinib within Greater China.

Aumolertinib is approved by the National Medical Products Administration (NMPA) of China for both first-line and second-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC.

Lerociclib

CDK4/6

1L / 2L advanced breast cancer

Phase 2

Metastatic endometrial cancer

Phase 3

Lerociclib (EQ132) is a novel, oral, potent, and selective small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Lerociclib was in-licensed from G1 Therapeutics.

Under the terms of the agreement, EQRx gains exclusive rights for lerociclib in the US, Europe, Japan, and all other global markets, excluding the Asia-Pacific region (except Japan).

Sugemalimab

PD-L1

1L metastatic NSCLC

Phase 3

Consolidation therapy in locally advanced/unresectable NSCLC

Phase 3

Sugemalimab (EQ165, CS1001) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Sugemalimab was discovered by CStone Pharmaceuticals, and EQRx has partnered with CStone Pharmaceuticals on the global development of sugemalimab. EQRx holds the development and commercialization rights to sugemalimab outside of Greater China. Pfizer, Inc. holds the exclusive development and commercialization rights to sugemalimab within Greater China.

Sugemalimab is approved by the National Medical Products Administration (NMPA) of China for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy and in combination with chemotherapy for the first-line treatment of patients with metastatic squamous and non-squamous NSCLC.

Nofazinlimab

PD-1

Hepatocellular carcinoma

Phase 3

Nofazinlimab (EQ176, CS1003) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Nofazinlimab was in-licensed from CStone Pharmaceuticals.

EQRx has worldwide rights to nofazinlimab outside of Greater China.

EQ121

JAK1

Immune-inflammatory indications

Phase 2

EQ121 is a novel, highly selective janus kinase-1 (JAK-1) inhibitor. EQ121 was in-licensed from Lynk Pharmaceuticals.

EQRx has worldwide rights to EQ121 outside of Greater China.

The safety and efficacy of these investigational compounds have not been established. There is no guarantee that the outcome of these studies will result in approval by a regulatory authority.

This pipeline describes investigational assets as of 2/23/2023.

View our Expanded Access Policy.

Abbreviations: 1L = first-line; 2L = second-line; CDK4/6 = cyclin-dependent kinase 4 and 6; EGFR = epidermal growth factor receptor; ENKTL = extra-nodal natural killer/T-cell lymphoma; JAK1 = Janus kinase 1; NSCLC = non-small cell lung cancer; PD-1 = programmed-death-1; PD-L1 = programmed death ligand-1.